ESPERION THERAPEUTICS INC. - COMMON STOCK

Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023

11 Aug 2023 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

08 Aug 2023 13:15:00 By Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2023 Financial Results

01 Aug 2023 03:00:00 By Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2023 Financial Results on August 1

17 Jul 2023 03:00:00 By Nasdaq GlobeNewswire

Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023

07 Jul 2023 05:00:00 By Nasdaq GlobeNewswire

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

28 Jun 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions

24 Jun 2023 11:30:00 By Nasdaq GlobeNewswire

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023

15 Jun 2023 11:30:00 By Nasdaq GlobeNewswire

Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023

08 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023

05 Jun 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

01 Jun 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

25 May 2023 13:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in Jefferies Healthcare Conference

24 May 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 May 2023 13:30:00 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2023 Financial Results

09 May 2023 04:00:02 By Nasdaq GlobeNewswire

Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9

04 May 2023 05:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in JMP Securities Life Sciences Conference

01 May 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion to Participate in Bank of America Securities 2023 Health Care Conference

27 Apr 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

25 Apr 2023 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

19 Apr 2023 05:42:01 By Nasdaq GlobeNewswire